The US Food and Drug Administration (FDA) has approved Novartis Rydapt (midostaurin, formerly PKC412) for two indications.

Available in 25mg capsules, Rydaptis an oral, multi-targeted inhibitor of several kinases that help in regulating multiple essential cell processes, preventing cancer cells’ ability to grow and multiply.

The drug can be used to treat acute myeloid leukaemia (AML) in newly diagnosed patients who are FMS-like tyrosine kinase 3 mutation-positive (FLT3+) along with chemotherapy.

The FDA has also approved Rydapt for the treatment of adults affected with advanced systemic mastocytosis (SM) that includes aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated haematological neoplasm (SM-AHN) and mast cell leukaemia.

Source:https://www.novartis.com/news/media-releases/novartis-receives-fda-approval-rydaptr-newly-diagnosed-flt3-mutated-acute